Synaptogenix Inc (SNPX)

[InTheTrenches]

RE: The slide describing 3 compassionate-use patients (presented by NTRP/Dr. Alkon):

Amazing results, albeit with a small n. April will give a more complete picture.

I'd like to see Neurotrope keep the Phase 2b patients on-drug past the 12-week cutoff, and continue to follow them for a year. If the April Phase 2b readout has efficacy and safety anywhere close to these 3 patients, and that efficacy and safety continues for a year, that could lead to an accelerated approval.

Most important takeaway from that slide:

"No other reports have ever shown comparable benefits in such severely demented patients - albeit in the absence of age-matched controls."